about
Detection of hepatitis C virus RNA by methods using phenol-chloroform or silica particlesDynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients.Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.Latent hepatitis B virus infection in childhood hepatocellular carcinoma. Analysis by polymerase chain reaction.Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report.Mother-to-child transmission of TT virus: sequence analysis of non-coding region of TT virus in infected mother-infant pairs.Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a.Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a.Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients.Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals.Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients.Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies.Acute self-limiting hepatitis C after possible sexual exposure: sequence analysis of the E-2 region of the infected patient and sexual partner.Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma.Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma.Hepatitis C virus infection in blood donors with indeterminate results in second-generation recombinant immunoblot assay.Virological patterns of hepatitis C virus in chronic hepatitis C with biochemical sustained response to interferon therapy.Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features.Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment.Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.The appropriate method of evaluating the dynamics of hepatitis B virus in patients receiving antiviral treatment: the other side of the coin.Hepatitis B virus binds to peripheral blood mononuclear cells via the pre S1 protein.Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study.Single-Nucleotide Polymorphism–Defined Class I and Class III Major Histocompatibility Complex Genetic Subregions Contribute to Natural Long-term Nonprogression in HIV InfectionA novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection
P50
Q27485660-65710E67-71D5-4DA5-8A13-87942FD2D288Q37176312-9EFF8C34-0772-47BA-94CF-B7665DD46856Q38597807-C356C3DF-15DA-435B-AB87-F0A44992B925Q38888859-F2118C76-4FEE-47D1-805C-514433050317Q39301797-F2320303-C9C8-4934-9483-6A36E8DD71DEQ40237283-241FB3A0-46DA-4DCD-9CA5-D1189032B92CQ40377822-AB68BC9E-7FC5-44AF-A740-DADE0DF473C7Q40667760-770C44F0-C512-4E62-9041-8DD01620D549Q40856569-EE88BEC9-CFA5-4936-9803-9A9F03CE3528Q41083621-E233B306-9732-4D1D-9DD0-BFD7739C5039Q41634185-45464B92-F06C-4C32-B283-F45DEA47E391Q42269060-6979A386-85FB-4706-A731-640044AB6BF5Q42669638-D2217B01-8E10-4BD4-BEB8-A23915BF6F2FQ42677372-1F2BE3F1-FC2D-4D6B-89AC-30E4BCA8A89FQ42980409-2F343079-19D5-4F24-97FD-56F86CB22674Q42980441-F671B704-C70F-48A2-BE3F-32DFE849EDFFQ42984494-F6C492BE-99C9-42F4-A9BC-8C50D0ECBDCBQ42985465-5269A8D5-05A2-4CEC-B279-FFBF7031BCA2Q42987087-3537EFAE-5C91-401B-9DDA-DA905C0820F5Q42988780-C82C88EC-2193-4989-A8A8-4596B73770FFQ42988991-0ABFDD42-71D7-4CC3-9BE0-217C9D8EF49DQ42989246-C04B1CE7-F1A8-4F85-A3B2-2C2A83A8117CQ42991126-55AAA02C-C584-4426-8FBE-B6AF58FD5F8BQ42996178-33EA9D6F-685C-4DF6-94FF-F6F06A2D40BCQ42996442-F16B1818-BF98-4A20-8E6D-BD7F37798F24Q43030175-B678D090-1259-496E-A541-3860933ED47CQ43030555-7F22AC30-2737-4BE7-B14D-EE069C6A6256Q43036292-00BD2FDB-70C9-461D-ACEC-AD5B530BD15CQ43037178-5685B1B8-5B24-4C11-9D35-718FB58DF229Q43040585-1E30D46D-DD5A-4F79-BAE0-5C2CB34C35A8Q43042283-C5633240-BD66-4CDE-88C4-876FCF44F7FBQ43046578-1BA43385-D8AB-4577-BC22-FA37686132A8Q43294586-5114B189-F08D-458A-A810-0421A3A96C27Q43529042-F61D6649-8275-4DD0-9C42-FC51F44723A0Q44470463-05A04994-B6F4-4E2E-9CE9-EE1604341737Q45423256-1A7D2EC7-D1A1-4F65-AD84-C318F2C17BFDQ45852666-F7E1473E-41F0-4B7D-93C7-49CDA8CE4552Q46959082-B4FE05D3-30FD-4003-8F17-DCCEF6F0640FQ56837762-F7E74666-24C4-47CD-BCEF-7231EEE32FB9Q56979536-10E223CB-E49F-4C79-B3A8-E46F0C60C34E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giulia Morsica
@ast
Giulia Morsica
@en
Giulia Morsica
@es
Giulia Morsica
@nl
Giulia Morsica
@sl
type
label
Giulia Morsica
@ast
Giulia Morsica
@en
Giulia Morsica
@es
Giulia Morsica
@nl
Giulia Morsica
@sl
prefLabel
Giulia Morsica
@ast
Giulia Morsica
@en
Giulia Morsica
@es
Giulia Morsica
@nl
Giulia Morsica
@sl
P106
P21
P31
P496
0000-0003-4891-5376